Merck revises down its COVID-19 drug efficacy
Merck & Co. Inc. and Ridgeback Biotherapeutics released on Friday an update on the study of their COVID-19 treatment molnupiravir, stating it reduces the risk of hospitalization or death by 30%. P…
Harry T. Partner's Academy & fpmarkets
NOI SIAMO UN GRUPPO DI LAVORO PER QUESTO NON TI CHIEDIAMO SOLDI. CON NOI NON SARAI SOLO
